Oregon Health & Science University’s Dr. Richard Weleber Receives Foundation Fighting Blindness’ Highest Research Honor
(Baltimore, Maryland) -- Richard Weleber, M.D., was recognized for over four decades of groundbreaking work including leadership of clinical trials for emerging retinal-disease therapies and innovations in retina imaging and functional evaluation, with the Foundation Fighting Blindness’ LLura Liggett Gund Award at the Foundation’s annual VISIONS Conference held this past weekend.
The Llura Liggett Gund Award recognizes retinal scientists who have consistently made the greatest contributions to retinal degenerative disease research. Retinal degenerative diseases, including macular degeneration, retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and Usher syndrome affect approximately 10 million Americans and millions more worldwide.
Dr. Weleber is a clinical researcher at the world-renowned Casey Eye Institute, Oregon Health & Science University. His career achievements are a remarkable list of scientific breakthroughs that hold the strong promise of restoring vision, including:
- Neurotech capsule for retinitis pigmentosa (RP) and dry age-related macular degeneration
- RPE65 gene therapy for Leber congenital amaurosis and RP
- StarGen gene therapy for Stargardt disease
- UshStat gene therapy for Usher syndrome type 1B
- AGTC’s gene therapies for achromatopsia and X-linked retinoschisis
- Valproic acid for dominant RP
“Dr. Weleber isn’t an extraordinary clinical researcher only because of his scientific achievements – which are in and of themselves highly laudable. He’s also special because of his support for the work of colleagues and the research mission as well as his compassion and caring for his patients,” says FFB’s Chief Research Officer Dr. Stephen Rose.
“Dr. Weleber’s role in launching, leading and facilitating clinical trials for emerging treatments has been indispensable and has helped propel the field forward in innumerable ways,” Rose added.